These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
6. Amyloid-β₂₅₋₃₅ induces impairment of cognitive function and long-term potentiation through phosphorylation of collapsin response mediator protein 2. Isono T; Yamashita N; Obara M; Araki T; Nakamura F; Kamiya Y; Alkam T; Nitta A; Nabeshima T; Mikoshiba K; Ohshima T; Goshima Y Neurosci Res; 2013 Nov; 77(3):180-5. PubMed ID: 23994236 [TBL] [Abstract][Full Text] [Related]
7. Regional differences in synaptic degeneration are linked to alpha-synuclein burden and axonal damage in Parkinson's disease and dementia with Lewy bodies. Frigerio I; Bouwman MMA; Noordermeer RTGMM; Podobnik E; Popovic M; Timmermans E; Rozemuller AJM; van de Berg WDJ; Jonkman LE Acta Neuropathol Commun; 2024 Jan; 12(1):4. PubMed ID: 38173031 [TBL] [Abstract][Full Text] [Related]
8. Regional Multiple Pathology Scores Are Associated with Cognitive Decline in Lewy Body Dementias. Howlett DR; Whitfield D; Johnson M; Attems J; O'Brien JT; Aarsland D; Lai MK; Lee JH; Chen C; Ballard C; Hortobágyi T; Francis PT Brain Pathol; 2015 Jul; 25(4):401-8. PubMed ID: 25103200 [TBL] [Abstract][Full Text] [Related]
9. Semaphorin3A signalling is mediated via sequential Cdk5 and GSK3beta phosphorylation of CRMP2: implication of common phosphorylating mechanism underlying axon guidance and Alzheimer's disease. Uchida Y; Ohshima T; Sasaki Y; Suzuki H; Yanai S; Yamashita N; Nakamura F; Takei K; Ihara Y; Mikoshiba K; Kolattukudy P; Honnorat J; Goshima Y Genes Cells; 2005 Feb; 10(2):165-79. PubMed ID: 15676027 [TBL] [Abstract][Full Text] [Related]
10. Collapsin response mediator protein-2 hyperphosphorylation is an early event in Alzheimer's disease progression. Cole AR; Noble W; van Aalten L; Plattner F; Meimaridou R; Hogan D; Taylor M; LaFrancois J; Gunn-Moore F; Verkhratsky A; Oddo S; LaFerla F; Giese KP; Dineley KT; Duff K; Richardson JC; Yan SD; Hanger DP; Allan SM; Sutherland C J Neurochem; 2007 Nov; 103(3):1132-44. PubMed ID: 17683481 [TBL] [Abstract][Full Text] [Related]
11. Lewy- and Alzheimer-type pathologies in midbrain and cerebellum across the Lewy body disorders spectrum. Sierra M; Gelpi E; Martí MJ; Compta Y Neuropathol Appl Neurobiol; 2016 Aug; 42(5):451-62. PubMed ID: 26810462 [TBL] [Abstract][Full Text] [Related]
12. Neuropathologically mixed Alzheimer's and Lewy body disease: burden of pathological protein aggregates differs between clinical phenotypes. Walker L; McAleese KE; Thomas AJ; Johnson M; Martin-Ruiz C; Parker C; Colloby SJ; Jellinger K; Attems J Acta Neuropathol; 2015 May; 129(5):729-48. PubMed ID: 25758940 [TBL] [Abstract][Full Text] [Related]
13. Phosphorylation of tau and alpha-synuclein in synaptic-enriched fractions of the frontal cortex in Alzheimer's disease, and in Parkinson's disease and related alpha-synucleinopathies. Muntané G; Dalfó E; Martinez A; Ferrer I Neuroscience; 2008 Apr; 152(4):913-23. PubMed ID: 18343584 [TBL] [Abstract][Full Text] [Related]
14. Neuritic pathology as a correlate of synaptic loss in dementia with lewy bodies. Revuelta GJ; Rosso A; Lippa CF Am J Alzheimers Dis Other Demen; 2008; 23(1):97-102. PubMed ID: 18276962 [TBL] [Abstract][Full Text] [Related]
15. (S)-Lacosamide Binding to Collapsin Response Mediator Protein 2 (CRMP2) Regulates CaV2.2 Activity by Subverting Its Phosphorylation by Cdk5. Moutal A; François-Moutal L; Perez-Miller S; Cottier K; Chew LA; Yeon SK; Dai J; Park KD; Khanna M; Khanna R Mol Neurobiol; 2016 Apr; 53(3):1959-1976. PubMed ID: 25846820 [TBL] [Abstract][Full Text] [Related]
16. The limbic and neocortical contribution of α-synuclein, tau, and amyloid β to disease duration in dementia with Lewy bodies. Ferman TJ; Aoki N; Crook JE; Murray ME; Graff-Radford NR; van Gerpen JA; Uitti RJ; Wszolek ZK; Graff-Radford J; Pedraza O; Kantarci K; Boeve BF; Dickson DW Alzheimers Dement; 2018 Mar; 14(3):330-339. PubMed ID: 29100980 [TBL] [Abstract][Full Text] [Related]
17. Lysosomal cathepsin D is upregulated in Alzheimer's disease neocortex and may be a marker for neurofibrillary degeneration. Chai YL; Chong JR; Weng J; Howlett D; Halsey A; Lee JH; Attems J; Aarsland D; Francis PT; Chen CP; Lai MKP Brain Pathol; 2019 Jan; 29(1):63-74. PubMed ID: 30051532 [TBL] [Abstract][Full Text] [Related]
18. aFGF Promotes Neurite Growth by Regulating GSK3β-CRMP2 Signaling Pathway in Cortical Neurons Damaged by Amyloid-β. Cao Q; Meng T; Man J; Peng D; Chen H; Xiang Q; Su Z; Zhang Q; Huang Y J Alzheimers Dis; 2019; 72(1):97-109. PubMed ID: 31561361 [TBL] [Abstract][Full Text] [Related]
19. A soluble tau fragment generated by caspase-2 is associated with dementia in Lewy body disease. Smith BR; Nelson KM; Kemper LJ; Leinonen-Wright K; Petersen A; Keene CD; Ashe KH Acta Neuropathol Commun; 2019 Jul; 7(1):124. PubMed ID: 31362787 [TBL] [Abstract][Full Text] [Related]
20. Distribution of cerebral amyloid deposition and its relevance to clinical phenotype in Lewy body dementia. Fujishiro H; Iseki E; Higashi S; Kasanuki K; Murayama N; Togo T; Katsuse O; Uchikado H; Aoki N; Kosaka K; Arai H; Sato K Neurosci Lett; 2010 Dec; 486(1):19-23. PubMed ID: 20851165 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]